1	Bioinfo-pharmacology: the example of therapeutic hypothermia
2	
3	Fei Liu ^{1,2,3,#} ; Xiangkang Jiang ^{1,2,3} , Mao Zhang ^{1,2,3,*}
4	
5	Author affiliations:
6	1. Department of Emergency Medicine, Second Affiliated Hospital of Zhejiang University,
7	Hangzhou 310009, Zhejiang Province, China.
8	2. Institute of Emergency Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province,
9	China.
10	3. Key Laboratory of The Diagnosis and Treatment of Severe Trauma and Burn of Zhejiang
11	Province, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.
12	
13	[#] The first 1 author is the first author.
14	* corresponding author: Prof. Mao Zhang
15	Email: <u>z2jzk@zju.edu.cn</u>
16	Telephone: +86 13757119125
17	
18	Declaration
19	Ethics approval and consent to participate.
20	Not applicable.
21	
22	Consent for publication
23	All authors allow the publication of this article.
24	
25	Availability of data and materials
26	All the data that support the findings of this study are available for email from authors.
27	
28	Competing interests
29 NO	TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. The authors have declared that they have no conflicts or interests.

30	
31	Funding
32	The authors have stated that no such relationships exist.
33	
34	Authors' contributions
35	FL designed the research and wrote the article. XJ drew the pictures. ZM modified the article and
36	analyzed the data.
37	
38	Acknowledge
39	We thank Zaizai Cao, Xiangjie Lin, and Yuanyuan Hao for the algorithm discussion.
40	
41	
42	

44 Abstract

Computer-aided drug discovery (CADD) is a widely used method for drug discovery 45 with many successes. Meanwhile, CADD has the limitation of analyzing multi-level 46 scores such as docking results of multiple proteins with multiple drugs. We propose a 47 method of PageRank to solve the problem. This method can make a comprehensive 48 ranking based on multi-level scores. Then we take an example of therapeutic 49 hypothermia (TH). Three levels of TH data were used in the article: the log2 50 foldchange (logFC) of proteins, the relative expression values of mRNA, and the 51 docking scores of proteins and molecules. After calculation, we get the 52 comprehensive drug rank and drug combination rank of each group of TH, which 53 means we can generate the rank of drug directly from bioinformatics. Based on this 54 method, we raised the concept of bioinfo-pharmacology. Given the high rationality 55 and compatibility of bioinfo-pharmacology, it can effectively enhance popular drug 56 discovery techniques such as the docking or pharmacophore model. Besides, it could 57 advance the application of precision medicine. 58 59 Keywords: computer-aided drug discovery (CADD); precision medicine; Therapeutic 60 hypothermia; virtual screening; 61

62

63

64

66 Introduction

Drug discovery is an expensive and time-demanding process that faces many challenges, including low hit discovery rates for high-throughput screening, among many others.[1,2] Methods of computer-aided drug discovery (CADD) can significantly speed up the pace of such screening and reduce the cost. Until now, CADD has achieved important results. [3–5]

Meanwhile, CADD also has limitations. Researchers can only get the best match for a 72 particular target (drug development), or the best match for a particular molecule 73 (network pharmacology[6]). As a result, most pharmacological studies currently work 74 single target. However, according bioinformatics 75 on а to databases, diseases/treatments exist multiple targets, which generate complex regulation 76 functions, in the different stages of diseases/treatments.[7] 77

Take therapeutic hypothermia as an example. Therapeutic hypothermia (TH) can limit the degree of some kinds of injuries in randomized trials[8] and animal experiments[9], and is even the only effective method for some diseases especially hypoxic-ischemic encephalopathy (HIE). HIE often causes severe neurological sequelae, which is the main reason for the poor prognosis of patients with stroke, shock, carbon monoxide poisoning, cerebral hemorrhage, and cardiac arrest.[10–12]

In the research based on TH, cold shock proteins especially cold-induced RNA binding protein (CIRP) show high expression [13] and rapid response [14]. CIRP has been shown to promote the translation of genes involved in DNA repair [15,16], telomerase maintenance[17], and genes associated with the translational machinery[18].

However, if CIRP leaks to the intercellular substance with cell swelling and rupture, it will become a harmful protein. Extracellular CIRP (eCIRP) showed a strong proinflammatory effect, leading to a heavier hypoxic injury.[19,20] Because of the habit of clinical medication, we cannot determine whether there are drugs that affect the therapeutic effect before and after the beginning of TH.

94 With the development of protein prediction technologies, especially AlphaFold2[21]

and RoseTTAFold[22], we can obtain the three-dimensional structure of proteins 95 more quickly and accurately. All target proteins' structures can be predicted, and their 96 97 best antagonists can be obtained by molecular docking. However, there is no technology for comprehensively ranking the cross-level data of numerical evaluation. 98 99 To solve the complex function differences by temporal and spatial distribution differences of proteins, we use personalization-weight-PageRank to rank drugs 100 targeting proteins predicted by AlphaFold2 and RoseTTAFold at different groups to 101 predict the best drugs or drug combinations for each group. Based on these, we came 102

103 up with the concept of bioinfo-pharmacology.

104 Method

105 Experiment design

As shown in Figure 1, the representative experiment of bioinfo-pharmacology is divided into 5 processes: 1. Protein or mRNA chosen by bioinformatics analysis; 2. Protein and drugs 3D structure acquisition and prediction; 3. Proteins' active sites prediction; 4. Drug/molecular group evaluation with target proteins; 5. PageRank of docking results, protein logFC, and mRNA expression. The experiment of animals or cells is referred by authors, but not forced. The biggest difference from previous studies is PageRank.

113

114 The data source of bioinformatics analysis

We retrieved the original data of mRNA expression under hypothermia treatment from the website of The National Center for Biotechnology Information (NCBI) (GSE54229). The research was reported by Sten et.al.[14] In their research, mouse embryonic fibroblasts were exposed to mild hypothermia (32°C) or normothermia (37°C) to gain the transcription response induced by hypothermia.

120

121 Expression Profile Analysis

122 The log2 fold-change (log2FC) and p-value were calculated for the normothermia

group. Top 3 log2FC mRNA with q-value < 0.05 were selected from each group to

124 enter the next step. If there exists mRNA with failed protein structure prediction, the

125 mRNA would be skipped.

126 R 3.6.1 was used to detect differential expressed compared to matched normothermia

samples. The clustering of genes was calculated by the "dist" and "hclust" function of

128 R. The visualization of gene expression and clustering is performed by the

129 "dendextend" package.

130

131 3D Data of proteins and small molecular drugs

132 All proteins were first searched on PubMed to see if there was protein clipping like

133 cleaved caspase-3[23].

Then the 3D structures of proteins were firstly searched from Protein Data Bank (PDB), which is used for biological-related ligand-protein interaction. In this article, no protein structure is listed on the PDB website. All the protein structures were predicted by AlphaFold2 and RoseTTAFold.

AlphaFold2 is developed by Google and is the champion of the 14th Critical Assessment of Structure Prediction (CASP14). In August 2021, AlphaFold submitted a structure prediction database for all proteins. RoseTTAFold is based on the Rosetta software which is designed for macromolecular modeling, docking, and design[24] RoseTTAFold also has good application[25] in the research of protein structure prediction. Finally, protein structures with fewer irregular regions will be selected for the next step.

The 3D structures of 8,697 drugs (DrugBank, 5.1.8) were downloaded from DrugBank Online (https://go.drugbank.com/). Approved, experimental, nutraceutical, and investigational drugs by Food and Drug Administration (FDA) are included. We split each drug molecule into a PDBQT-format file and minimized the energy separately for docking with proteins.

150

151 Visualize evolutionary conservation and active site prediction

152 Visualize evolutionary conservation was performed by the ConSurf server[26]. In a

typical ConSurf application, through BLASTed[27] against the UNIREF-90

database[28] and aligning using MAFFT[29], the evolutionarily conserved positions

are analyzed by the Rate4Site algorithm.

156 Then, the Consensus approach-D (COACH-D) [30] was used to predict the active site

- 157 of target proteins. The COACH-D use five different methods to predict the binding
- sites of protein ligands. Four of these methods are COFAC-TOR[31], FINDSITE[32],

159 TM-SITE[33], and S-SITE[33]. These methods predict binding sites by matching the

160 query structure and sequence with the ligand-binding template in BioLiP[34], which

161 is a semi-manual functional database[35] based on the PDB.

162

163 Virtual screening of potential compounds

164 To evaluate the hit compounds obtained from DrugBank and calculate their

165 interaction and binding posture in the active site of target proteins, the molecular

166 docking method was carried out through QuickVina 2[36]. QuickVina 2 uses the

167 calculation of shape and electrostatic potential similarity of binding pockets to select

168 molecules, which may exhibit binding patterns like those of binding pockets.

169 3D files of target proteins were dehydrated, hydrogenated. Then proteins were saved

170 as PDBQT files using AutoDock. AutoDock assisted in assigning Gasteiger charges

and adding polar hydrogen atoms to both the proteins and the compounds.

172

173 Molecular dynamics simulation

174 The molecular dynamics (MD) simulation was performed by Gromacs[37]. Firstly, a

175 protein-drug complex was prepared, including adding hydrogenation and balancing

176 charge. Then, we add a solvent so that the target protein and drug small molecules are

177 coated. The forcefield was Chemistry at HARvard Macromolecular Mechanics 36

178 (CHARMm 36). The simulation time is set as 50ns for the speed of calculation. The

179 simulation temperature is 309.15K (36°C) and the pressure is 1 atm. Root mean

180 square deviation (RMSD) and root mean square fluctuation (RMSF) were calculated

181 based on the first frame.

182

183 Personalization-weight-PageRank

We use personalization-weight-PageRank to rank cross level data. PageRank is a comprehensive rank algorithm designed by Google and named after Larry Page.[38] It is one of the most famous ranking algorithms of network nodes based on Markov process. PageRank has been applied in medical domains with success.[39,40]

Personalization and weight represent 3 different levels of score data. The weight of
PageRank allows all nodes to be initially assigned different weights/probabilities.[41]

190 In this article, the weights of rank were set to docking values of proteins and drugs.

191 The higher the docking value, the higher the connection rate of the complex.

Personalization of PageRank reinforces the connection intensity between the nodes, 192 which makes the result more personalized and realistic[42]. In this article, 193 personalization is influenced by protein functions. If the protein performs a negative 194 influence such as promoting apoptosis, the personalization will be calculated by 195 2^(fold change) to ensure they are more than 1. Meanwhile, if the protein plays a 196 positive role in the group, the personalization will be set as 1/(fold change + 1) to less 197 than 1. The personalization values of all the drugs are set to 0 to prevent iterations of 198 the drugs themselves from going wrong. 199

The calculation process is like putting all proteins and all drugs in the solution, then simulating the connections between all proteins and drugs by calculation. The damping factor is set to 0.85 to simulate the metabolism of proteins and drugs.

203 The whole calculation is based on Python 3.8.10. The relating python libraries include

204 NetworkX, Pandas, and NumPy. We use Pandas and NumPy to import all the docking

205 data into a matrix for PageRank calculating. The protein expression value is then

206 imported by the PageRank personalization parameter of NetworkX. Lastly, we can get

207 a comprehensive ranking of drugs.

208

209 Prediction and Rank of combined pharmacotherapy

210 In addition to the comprehensive ranking of drugs, we also try to generate the rank of

drug combinations. Similarly, the calculation places all drugs of combination and

212 target proteins in a solution to bind free.

First, all drugs will be grouped according to the docking results of drugs in each

214 combination. In this article, to reduce the amount of calculation, we selected the

TOP20 drugs of each protein to include in the drug combination pool. Then, all the

combinations were performed personalization-weight-PageRank against all protein

217 targets. The sum of each score of all drugs in the combination is the final score of the

218 combination. Lastly, we get the rank of combinations.

219 To make the distribution of combinations more clear, we propose drug-protein-

- 220 expression fit score (DPEFS) to show the data distribution pattern. The calculation is
- as follows: The PageRank values of all proteins were summed by multiplying logFC,
- then divided by the total PageRank values of drugs, and finally divided by the
- 223 PageRank values of specific proteins for standardized calculation. It is used for
- standardized calculation for comparing different combinations.
- 225 DPEFS evaluates the combination by referring to the protein expression trend. The
- higher the DPEFS, the better the fitness. In actual drug design, DPEFS is relatively
- high and PageRank score is relatively low, indicating that drugs of combination are
- relatively moderate, which suggests a negative outcome. All code can be found in
- 229 GitHub (https://github.com/FeiLiuEM/PageRank-weight-drug).

Result 230

- Expression analysis and clustering of hypothermia 231
- Figure 2 shows the expressions of different mRNA of different groups after 232
- hypothermia. From the inside to the outside, the rings were divided into hypothermia 233
- 0.5h group, hypothermia 1H group, hypothermia 2H group, hypothermia 4H group, 234
- hypothermia 8h group, and hypothermia 18h group. 235
- As shown in Table 1, in each group, we selected the top 3 expression protein targets. 236
- In the Hypothermia 0.5h group, the target proteins are circadian-associated 237
- transcriptional repressor (CIART), Glutathione-specific gamma-238
- glutamylcyclotransferase 1 (CHAC1), and Uridine diphosphate glucose 239
- pyrophosphatase nudix hydrolase 22 (NUDT22). The target proteins of the 240
- Hypothermia 1h group are CHAC1, corneodesmosin (CDSN), and Nuclear receptor 241
- subfamily 1 group D member 1 (NR1D1). The target proteins of the Hypothermia 2h 242
- group are cold-induced RNA-binding protein (CIRP), armadillo repeat-containing X-243
- linked protein 5 (ARMCX5), and coiled-coil domain-containing protein 122 244
- (CCDC122). The target proteins of the Hypothermia 4h group are CIRP, receptor 245
- activity-modifying protein 3 (RAMP3), and carcinoembryonic antigen-related cell 246
- adhesion molecule 1 (CEACAM1). The target proteins of the Hypothermia 4h group 247
- are the same: CIRP, RAMP3, and NAD(P)H dehydrogenase [quinone] 1 (NQO1). 248
- Within the targets, CHAC1 could enhance apoptosis[43]. NUDT22 is an Mg²⁺-249
- 250 dependent UDP-glucose and UDP-galactose hydrolase[44], while high glucose shows
- a negative effect in HIE like stroke[45]. CCDC122 potentially pro-inflammatory[46]. 251
- CIRP can effectively reduce cell death in the early stage of hypothermia therapy. 252
- However, it has a strong pro-inflammatory effect outside the cell, leading to cell 253
- killing. There is no definitive research on the timing of this shift. Referring to the 254
- previous article[47], we conservatively believed that CIRP could be identified as a 255
- 256 negative protein from the 8H group. CEACAM1[48] and NQO1[49] promote
- apoptosis. All the other targets are shown protective effects or don't have enough data. 257
- 258 The personalization values were calculated in Table 1. All the structures of target

259 proteins in Figure 3 were obtained by the rules in the section of Materials and

- 260 Methods.
- 261

262 Visualize evolutionary conservation and Structure-Function Relationship-Based

263 Binding Site Prediction

264 The conservation analysis of all the target proteins was listed in Figure 4A-K. The

redder the amino acid, the higher possibility the amino acid sequence with function.

266 Then we identified its structure-function relationship by the COACH-D server. The

267 results showed a familiar result of conservation analysis listed in Figure 4L-V. As

shown in Table 2, the range around 3-5 Å of the active site was used for the setting of

the receptor pocket of the target proteins that were used for virtual screening.

270

271 Virtual Screening of target proteins' Antagonists

272 We utilized the virtual screening technique to identify potential antagonists exhibiting

an adequate binding affinity. We started with a chemical database consisting of 8,697

drug molecules and isolated a set of compounds satisfying the threshold of a high

docking score. The results of the best match complexes are shown in Figure 5 and all

the results are listed in the Additional file Table 1.

277

278 MD Simulations and Binding Free Energy Analysis

279 We performed MD simulation of 11 complexes to measure the stability of the protein-

280 ligand complex. RMSD (root-mean-square deviation) profiles of the protein are

shown in Figure 6A, which indicates that all systems were relatively stable during the

282 entire simulation run. Moreover, RMSF profiles of protein are measured to evaluate

the moving of each amino acid. All proteins are available for further analysis (Figure

284 6B).

285 The RMSD of drug atoms was also conducted to predict the stability of the atoms in

286 docked complexes (Figure 6C). Most compounds exhibited a consistently low RMSD,

suggesting that these compounds formed stable complexes.

288

- 289 Drug rank of TH in different groups
- 290 We rank all drugs by PageRank. First, we PageRank all the drugs and get the results
- in table3. 2-drug-combinations are ranked in Table 4 and 3-drug-combinations in the
- additional file Table 2. For comprehensive rank, the results of PageRank were listed.
- 293 For drug-combination ranks, the percentages of each drug's value in the combination
- 294 were calculated. And DPEFS was calculated for analyzing the distribution differences
- 295 of drug combinations.

297 **Discussion**

298 In this paper, a new pharmacological method — bioinfo-pharmacology is proposed,

using therapeutic hypothermia as an example. By bioinformatics analysis, protein

300 structure prediction, and PageRank, we provide a direct bridge between

301 symptom/treatment and drug design.

AlphaFold2 and RoseTTAFold were used for protein structure prediction. And the 302 number of proteins selected by AlphaFold2 in this research was close to that of 303 RoseTTAFold. During the process of protein structure prediction, we found that for 304 some proteins, the structures predicted by RoseTTAFold have less irregular structure 305 than that of AlphaFold2. This may be due to the 2D distance map level transformed 306 and integrated by RoseTTAFold during neural network training[22], while 307 AlphaFold2 only paired structure database and genetic database. We also find a 308 phenomenon that the predicted protein structures were relatively unstable under 309 molecular dynamics simulation than preview reports of other protein structures 310 311 detected by X-ray.

The application of PageRank is suitable. First, the combination of drug molecules is a memoryless stochastic process, which meets the qualifications of the Markov process. Second, our method aims to simulate the binding process in *vivo*. The comprehensive analysis involves free docking of proteins with all drugs. Drug combination analysis is to put proteins and related drugs into the solution for docking.

Besides, the method has good compatibility for the wide compatibility of PageRank. In theory, all the technologies with numerical results can be ranked by the method. In this paper, for the lack of bioinformatics data of Therapeutic hypothermia, we only do a basic analysis. If there is more data of the TH, the analysis of Weighted Gene Coexpression Network Analysis (WGCNA)[50] or Gene Regulatory Networks (GRN)[51] will be better because they could provide more plausible results of protein list.

Meanwhile, pharmacophore models[52] can use bioinfo-pharmacology for highly efficient drug design. After ranking, top-ranked pharmacophore fingerprints or

alignments could be linked together for good pharmacological effects. And ultimately, 326 improve the therapeutic effect of drugs, reduce toxic and side effects, improve the 327 success rate of clinical trials of new drugs, save drug research and development costs. 328 For the same reason, this method can also enhance network pharmacology and 329 chrono-pharmacology. Network pharmacology[6] focuses on the application of 330 protein network structures to improve drug discovery. By PageRank, the association 331 between protein network structures and different drugs can be more accurately 332 understood through comprehensive drug analysis of multiple targets rather than the 333 previous single target. Thus, it has a good promotion effect on traditional herbal 334 medicine research. In traditional herbal medicine, there may be multiple drug 335 molecules in a single herb, and its complex multi-target problem can be efficiently 336 analyzed by new methods. Another influenced area is chrono-pharmacology. Chrono-337 pharmacology[53] is expert in the adaptation and anticipation mechanisms of the 338 body concerning clock system regulation of various kinetic and dynamic pathways, 339 340 including absorption, distribution, metabolism, and excretion of drugs and nutrients. By bioinfo-pharmacology, researchers can develop drugs for different time groups, 341 which will bring precision medicine to this kind of diseases. 342

Based on these potential improvements and high compatibility, we propose the concept of bioinfo-pharmacology for its ability to directly apply bioinformatics for drug discovery. Bioinfo-pharmacology is a method that uses bioinformatics, protein structure prediction, and PageRank for drug design. The main feature is that multiple targets target multiple molecules/pharmacophores. Overall, this approach builds a bridge between disease/treatment and drug development, bringing up more possibilities for future drug development.

350 This research has some defects. 1: For the speed of calculating, we only choose the

top 3 mRNAs and use the top 1 complex for MD simulation. Furthermore, the

duration of molecular dynamics simulation is set to 50ns. These operations mitigate

353 the rationality of the results relatively; 2. Theoretically, pharmacophore modeling has

a better improvement under PageRank. But considering the purpose of the article, we

- 355 use AutoDock to dock all the marketing drugs.
- 356 In summary, this paper proposes a new method of pharmacology—bioinfo-
- 357 pharmacology by PageRank. The results provide medical clues for the treatment of
- 358 TH. Besides, it can help the functional research of proteins at the molecular level for
- 359 experimental biologists. In addition, we can do drug combination analysis of drugs
- 360 similarly. The new approach could have a huge impact on precision medicine, drug
- 361 design, and traditional herbal medicine in the future.
- 362
- 363
- 364
- 365

366	Reference
367	1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the
368	pharmaceutical industry: New estimates of R&D costs. J Health Econ.
369	2016;47:20–33.
370	2. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early
371	drug discovery: Principles of early drug discovery. Br J Pharmacol.
372	2011;162:1239–49.
373	3. Li R, Li Y, Liang X, Yang L, Su M, Lai KP. Network Pharmacology
374	and bioinformatics analyses identify intersection genes of niacin and
375	COVID-19 as potential therapeutic targets. Brief Bioinform.
376	2021;22:1279–90.
377	4. Gandasi NR, Yin P, Omar-Hmeadi M, Ottosson Laakso E, Vikman
378	P, Barg S. Glucose-Dependent Granule Docking Limits Insulin
379	Secretion and Is Decreased in Human Type 2 Diabetes. Cell Metab.
380	2018;27:470-478.e4.
381	5. Cypionka A, Stein A, Hernandez JM, Hippchen H, Jahn R, Walla
382	PJ. Discrimination between docking and fusion of liposomes
383	reconstituted with neuronal SNARE-proteins using FCS. Proc Natl
384	Acad Sci U S A. 2009;106:18575–80.
385 386	6. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–90.
387	7. Wooller SK, Benstead-Hume G, Chen X, Ali Y, Pearl FMG.
388	Bioinformatics in translational drug discovery. Biosci Rep.
389	2017;37:BSR20160180.
390	8. Lascarrou J-B, Merdji H, Le Gouge A, Colin G, Grillet G,
391	Girardie P, et al. Targeted Temperature Management for Cardiac
392	Arrest with Nonshockable Rhythm. N Engl J Med. 2019;381:2327–37.
393	9. Kim JY, Kim JH, Park J, Beom JH, Chung SP, You JS, et al.
394	Targeted Temperature Management at 36 °C Shows Therapeutic
395	Effectiveness via Alteration of Microglial Activation and Polarization
396	After Ischemic Stroke. Transl Stroke Res. 2021;
397	10. Hosseini M, Wilson RH, Crouzet C, Amirhekmat A, Wei KS,
398	Akbari Y. Resuscitating the Globally Ischemic Brain: TTM and
399	Beyond. Neurother J Am Soc Exp Neurother. 2020;17:539–62.
400	11. Hazinski MF, Nolan JP, Aickin R, Bhanji F, Billi JE, Callaway
401	CW, et al. Part 1: Executive Summary: 2015 International Consensus
402	on Cardiopulmonary Resuscitation and Emergency Cardiovascular
403	Care Science With Treatment Recommendations. Circulation.
404	2015;132:S2-39.
405	12. Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J,
406	Chiche J-D, et al. Intensive care unit mortality after cardiac arrest:
407	the relative contribution of shock and brain injury in a large cohort.
408	Intensive Care Med. 2013;39:1972–80.
409 410	13. Rosenthal L-M, Leithner C, Tong G, Streitberger KJ, Krech J, Storm C, et al. RBM3 and CIRP expressions in targeted temperature

411 412	management treated cardiac arrest patients-A prospective single center study. PloS One. 2019;14:e0226005.
413	14. Ilmjärv S, Hundahl CA, Reimets R, Niitsoo M, Kolde R, Vilo J, et
414	al. Estimating differential expression from multiple indicators.
415	Nucleic Acids Res. 2014;42:e72.
416	15. Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, Carrier F.
417	Functional significance for a heterogenous ribonucleoprotein A18
418	signature RNA motif in the 3'-untranslated region of ataxia
419	telangiectasia mutated and Rad3-related (ATR) transcript. J Biol
420	Chem. 2010;285:8887–93.
421	16. Haley B, Paunesku T, Protić M, Woloschak GE. Response of
422	heterogeneous ribonuclear proteins (hnRNP) to ionising radiation
423	and their involvement in DNA damage repair. Int J Radiat Biol.
424	2009;85:643–55.
425	17. Zhang Y, Wu Y, Mao P, Li F, Han X, Zhang Y, et al. Cold-
426	inducible RNA-binding protein CIRP/hnRNP A18 regulates
427	telomerase activity in a temperature-dependent manner. Nucleic
428	Acids Res. 2016;44:761–75.
429	18. Zhong P, Huang H. Recent progress in the research of cold-
430	inducible RNA-binding protein. Future Sci OA. 2017;3:FSO246.
431	19. Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T,
432	Iijima H, et al. Stress response protein cirp links inflammation and
433	tumorigenesis in colitis-associated cancer. Cancer Res. 2014;74:6119–
434	28.
435	20. Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S,
436	Watanabe T, et al. Stress Response Protein RBM3 Promotes the
437	Development of Colitis-associated Cancer. Inflamm Bowel Dis.
438	2017;23:57–65.
439 440 441	21. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.
442	22. Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S,
443	Lee GR, et al. Accurate prediction of protein structures and
444	interactions using a three-track neural network. Science.
445	2021;373:871–6.
446	23. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et
447	al. Caspase-3-generated fragment of gelsolin: effector of
448	morphological change in apoptosis. Science. 1997;278:294–8.
449	24. Leman JK, Weitzner BD, Lewis SM, Adolf-Bryfogle J, Alam N,
450	Alford RF, et al. Macromolecular modeling and design in Rosetta:
451	recent methods and frameworks. Nat Methods. 2020;17:665–80.
452	25. Humphreys IR, Pei J, Baek M, Krishnakumar A, Anishchenko I,
453	Ovchinnikov S, et al. Computed structures of core eukaryotic protein
454	complexes. Science. 2021;eabm4805.
455	26. Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et

456	al. ConSurf 2016: an improved methodology to estimate and visualize
457	evolutionary conservation in macromolecules. Nucleic Acids Res.
458	2016;44:W344-350.
459 460	27. Biegert A, Söding J. Sequence context-specific profiles for homology searching. Proc Natl Acad Sci U S A. 2009;106:3770–5.
461	28. Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt
462	Consortium. UniRef clusters: a comprehensive and scalable
463	alternative for improving sequence similarity searches. Bioinforma
464	Oxf Engl. 2015;31:926–32.
465	29. Katoh K, Standley DM. MAFFT multiple sequence alignment
466	software version 7: improvements in performance and usability. Mol
467	Biol Evol. 2013;30:772–80.
468	30. Wu Q, Peng Z, Zhang Y, Yang J. COACH-D: improved protein-
469	ligand binding sites prediction with refined ligand-binding poses
470	through molecular docking. Nucleic Acids Res. 2018;46:W438–42.
471 472 473	31. Roy A, Yang J, Zhang Y. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. Nucleic Acids Res. 2012;40:W471-477.
474	32. Brylinski M, Skolnick J. A threading-based method (FINDSITE)
475	for ligand-binding site prediction and functional annotation. Proc
476	Natl Acad Sci U S A. 2008;105:129–34.
477 478 479	33. Yang J, Roy A, Zhang Y. Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinforma Oxf Engl. 2013;29:2588–95.
480	34. Yang J, Roy A, Zhang Y. BioLiP: a semi-manually curated
481	database for biologically relevant ligand-protein interactions. Nucleic
482	Acids Res. 2013;41:D1096-1103.
483	35. Rose PW, Prlić A, Altunkaya A, Bi C, Bradley AR, Christie CH, et
484	al. The RCSB protein data bank: integrative view of protein, gene
485	and 3D structural information. Nucleic Acids Res. 2017;45:D271–81.
486	36. Alhossary A, Handoko SD, Mu Y, Kwoh C-K. Fast, accurate, and
487	reliable molecular docking with QuickVina 2. Bioinforma Oxf Engl.
488	2015;31:2214–6.
489 490 491	37. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701–18.
492	38. Page L, Brin S, Motwani R, Winograd T. The PageRank Citation
493	Ranking: Bringing Order to the Web. [Internet]. Stanford InfoLab;
494	1999 Nov. Report No.: 1999–66. Available from:
495	http://ilpubs.stanford.edu:8090/422/
496	39. Kalecky K, Cho Y-R. PrimAlign: PageRank-inspired Markovian
497	alignment for large biological networks. Bioinforma Oxf Engl.
498	2018;34:i537–46.
499	40. Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends

500	in the development of miRNA bioinformatics tools. Brief Bioinform.
501	2019;20:1836–52.
502	41. Xing W, Ghorbani A. Weighted PageRank algorithm. Proc
503	Second Annu Conf Commun Netw Serv Res 2004. 2004. p. 305–14.
504	42. Haveliwala T, Kamvar S, Jeh G. An Analytical Comparison of
505	Approaches to Personalizing PageRank [Internet]. Stanford; 2003
506	Jun. Report No.: 2003–35. Available from:
507	http://ilpubs.stanford.edu:8090/596/
508	43. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ.
509	CHAC1/MGC4504 is a novel proapoptotic component of the
510	unfolded protein response, downstream of the ATF4-ATF3-CHOP
511	cascade. J Immunol Baltim Md 1950. 2009;182:466–76.
512	44. Carter M, Jemth A-S, Carreras-Puigvert J, Herr P, Martínez
513	Carranza M, Vallin KSA, et al. Human NUDT22 Is a UDP-
514	Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold.
515	Struct Lond Engl 1993. 2018;26:295-303.e6.
516	45. Zhang S, Zuo W, Guo X-F, He W-B, Chen N-H. Cerebral glucose
517	transporter: the possible therapeutic target for ischemic stroke.
518	Neurochem Int. 2014;70:22–9.
519	46. Leturiondo AL, Noronha AB, Mendonça CYR, Ferreira C de O,
520	Alvarado-Arnez LE, Manta FS de N, et al. Association of NOD2 and
521	IFNG single nucleotide polymorphisms with leprosy in the Amazon
522	ethnic admixed population. PLoS Negl Trop Dis. 2020;14:e0008247.
523	47. Denning N-L, Yang W-L, Hansen L, Prince J, Wang P. C23, an
524	oligopeptide derived from cold-inducible RNA-binding protein,
525	suppresses inflammation and reduces lung injury in neonatal sepsis.
526	J Pediatr Surg. 2019;54:2053–60.
527	48. Zhao C, Dang Z, Sun J, Yuan S, Xie L. Up-regulation of
528	microRNA-30b/30d cluster represses hepatocyte apoptosis in mice
529	with fulminant hepatic failure by inhibiting CEACAM1. IUBMB Life.
530	2020;72:1349–63.
531	49. Feng Y, Cui R, Li Z, Zhang X, Jia Y, Zhang X, et al. Methane
532	Alleviates Acetaminophen-Induced Liver Injury by Inhibiting
533	Inflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and
534	Apoptosis through the Nrf2/HO-1/NQO1 Signaling Pathway. Oxid
535	Med Cell Longev. 2019;2019:7067619.
536 537	50. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
538	51. Alexiou A, Chatzichronis S, Perveen A, Hafeez A, Ashraf GM.
539	Algorithmic and Stochastic Representations of Gene Regulatory
540	Networks and Protein-Protein Interactions. Curr Top Med Chem.
541	2019;19:413–25.
542 543	52. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2014;66:334–95.
544	53. Tahara Y, Shibata S. Chrono-biology, chrono-pharmacology, and

chrono-nutrition. J Pharmacol Sci. 2014;124:320-35. 545

Group	Target	logFC	Personalization
	CIART	0.46	0.42
0.5h	CHAC1	0.43	1.34
	NUDT22	0.40	1.32
	CDSN	0.52	0.41
1h	NR1D1	0.50	0.41
	CHAC1	0.50	1.41
	CIRP	0.80	0.36
2h	ARMCX5	0.66	0.39
	CCDC122	0.49	1.41
	CIRP	1.17	0.31
4h	RAMP3	0.91	0.35
	CEACAM1	0.87	1.82
	CIRP	1.57	2.97
8h	RAMP3	1.33	0.28
	NQO1	1.18	2.27
	CIRP	1.71	3.27
18h	NQO1	1.55	2.93
	RAMP3	1.32	0.29

Table 1. The target proteins of different groups.

Protein name	protein source	Х	Y	Z	LEN-X	LEN-Y	LEN-Z
ARMCX5	RoseTTAFold	-7.06	31.20	-43.05	29.25	28.50	24.75
CDSN	RoseTTAFold	51.80	53.51	31.17	39.75	20.25	21.00
CEACAM1	AlphaFold2	-41.13	3.42	5.67	39.75	22.50	22.50
CHAC1	AlphaFold2	-3.04	-0.53	0.22	23.25	25.50	35.25
CIART	RoseTTAFold	36.79	-16.59	-36.23	28.50	38.25	22.50
CIRP	RoseTTAFold	14.48	2.86	-9.56	17.25	15.00	19.50
NQO1	AlphaFold2	-1.86	-16.32	-9.20	29.25	29.25	28.50
NR1D1	RoseTTAFold	0.34	35.70	10.28	39.75	25.50	24.75
NUDT22	AlphaFold2	10.08	-12.04	14.09	17.25	38.25	22.50
RAMP3	AlphaFold2	0.00	-10.93	-5.29	24.00	24.00	21.00
CCDC122	RoseTTAFold	119.27	23.34	8.09	36.00	47.25	47.25

Table 2. The docking parameters of target proteins.

Gro up	Drug	weighted_personalized_PageRan k (*10 ⁻⁴)
1.0.5	Fluzoparib	0.81
n0.5	Lorecivivint	0.80
n	Vactosertib	0.80
	Lorecivivint	0.81
h1h	AC-430	0.81
	Raltegravir	0.80
	Phthalocyanine	0.90
h2h	Vazegepant	0.87
	Bemcentinib	0.86
	Phthalocyanine	0.85
h4h	3-(2- AMINOQUINAZOLI N-6-YL)-4- METHYL-N-[3- (TRIFLUOROMETH YL)PHENYL]BENZ AMIDE Bemcentinib	0.84
	Phthalocyanine	0.87
h8h	MK-3207	0.86
	Lifirafenib	0.85
	Phthalocyanine	0.87
h18h	MK-3207	0.86
	Lifirafenib	0.85

	TT 1 1 2	- T -1	1 .	1 0	1 1	1.00
556	Iable 3	I he con	inrehensive	rank of	drugs at	different grouns
330	Table 5.		iprenensive	Tank OI	unugs at	uniterent groups.

Table 4.	Rank	of 2	drug	combinations	ofd	lifferent	group.
14010 1.	runn		urug	comonations	01 0		Sroup.

	drug1	drug2	Pag- eRank value of drug1	per- sentage	Pag- eRank value of drug2	per- sentage	personal- ized_weight_PageRank	Drug- pro- tein- expres- sion fit score
	Lorecivivint	Fluzoparib	0.41	49.85	0.42	50.15	0.83	2.30
h0.	Vactosertib	Fluzoparib	0.41	49.56	0.42	50.44	0.83	2.33
5h	2'-deoxy-N-(naphthalen-1- ylmethyl)guanosine 5'-(dihydrogen phosphate)	Fluzoparib	0.41	49.68	0.42	50.32	0.83	2.32
	Lorecivivint	AC-430	0.41	49.67	0.42	50.33	0.83	4.36
h1h	Lorecivivint	Raltegravir	0.42	50.12	0.41	49.88	0.83	4.40
	Lorecivivint	Vactosertib	0.42	50.21	0.41	49.79	0.83	4.37
	Phthalocyanine	Vazegepant	0.42	51.42	0.40	48.58	0.82	4.65
h2h	Phthalocyanine	Bemcentinib	0.43	51.84	0.40	48.16	0.82	4.71
	Phthalocyanine	Lifirafenib	0.43	52.28	0.39	47.72	0.82	4.64
h4h	3-(2-AMINOQUINAZOLIN-6-YL)- 4-METHYL-N-[3- (TRIFLUOROME- THYL)PHENYL]BENZAMIDE	CD564	0.41	50.25	0.41	49.75	0.82	1.60

	Adapalene	3-(2-AMINOQUINAZOLIN-6-YL)- 4-METHYL-N-[3- (TRIFLUOROME- THYL)PHENYL]BENZAMIDE	0.41	49.90	0.41	50.10	0.82	1.60
	3-(2-AMINOQUINAZOLIN-6-YL)- 4-METHYL-N-[3- (TRIFLUOROME- THYL)PHENYL]BENZAMIDE	Phthalocyanine	0.42	50.52	0.41	49.48	0.82	1.60
h8h	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	3.94
	Phthalocyanine	Lifirafenib	0.42	50.17	0.41	49.83	0.83	3.93
	Lifirafenib	MK-3207	0.41	49.75	0.42	50.25	0.83	3.94
h18 h	Phthalocyanine	MK-3207	0.41	49.91	0.41	50.09	0.83	4.95
	Lifirafenib	MK-3207	0.41	49.77	0.42	50.23	0.83	4.95
	Phthalocyanine	Lifirafenib	0.42	50.14	0.41	49.86	0.83	4.94

medRxiv preprint doi: https://doi.org/10.1101/2022.03.07.22271997; this version posted March 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint in preprint in the second se perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Representative workflow for bioinfo-pharmacology drug design. 1

- 14 Figure 2. Circular visualization of expression patterns and clustering of hypothermia
- treatment. Red indicates gene upregulation and blue indicates downregulation. 15



33

Figure 3. The 3D structures of target proteins. A. ARMCX5; B. CCDC; C. CDSN; D.

CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J. NUDT22; K.

RAMP3.



- 55 Figure 4. The ConSurf analysis and predicted active sites of target proteins. The upper
- 56 11 pictures are ConSurf analysis results. The last 11 pictures are predicted active sites.
- 57 A&L. ARMCX5; B&M. CCDC; C&N. CDSN; D&O. CEACAM1; E&P. CHAC1;
- 58 F&Q. CIART; G&R. CIRP; H&S. NQO1; I&T. NR1D1; J&U. NUDT22; K&V.
- 59 RAMP3. The redder the amino acid, the more conservative it is. The greener the color,
- 60 the less conservative it is.



62

Figure 5. The best docking molecular for each protein. A. ARMCX5; B. CCDC; C.

CDSN; D. CEACAM1; E. CHAC1; F. CIART; G. CIRP; H. NQO1; I. NR1D1; J.

NUDT22; K. RAMP3.



Figure 6. The RMSD and RMSF of MD simulation. A. The RMSD of proteins. B. The 71

RMSF of proteins. C. The RMSD of each molecular of proteins. 72

